TrialArthritis & rheumatology (Hoboken, N.J.)2022

Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.

Eric L Matteson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.